Search

Displaying results 1311 - 1320 of 3020 in total
  1. Drug

    Telisotuzumab vedotin

    go.drugbank.com/drugs/DB15104
    ApprovedInvestigational

    Telisotuzumab vedotin is an antibody-drug conjugate comprising [telisotuzumab], a c-Met-directed humanized IgG1κ monoclonal antibody, conjugated to monomethyl auristatin E (MMAE), a small molecule microtubule-disrupting … [L53193] Telizotuzumab vedotin-tllv was approved by the US FDA in May 2025 for previously treated advanced NSCLC patients with high c-Met protein overexpression,[L53158,L53183] becoming the first treatment

  2. Indication

    Pregnancy

    go.drugbank.com/conditions/DBCOND0018394
    Drugs: Estradiol dienanthate · Levonorgestrel · Medroxyprogesterone acetate · Norethindrone enanthate · Progesterone
    Synonyms: Gravid
  3. Drug

    Dacarbazine

    go.drugbank.com/drugs/DB00851
    ApprovedInvestigational

    (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.

  4. Target

    Eukaryotic translation initiation factor 2-alpha kinase 1

    go.drugbank.com/bio_entities/BE0009433
    TargetHumans

    Thanks to this unique heme-sensing capacity, plays a crucial role to shut off protein synthesis during acute heme-deficient conditions (By similarity). … This binding occurs with moderate affinity, allowing it to sense the heme concentration within the cell: heme depletion relieves inhibition and stimulates kinase activity, activating the ISR (By similarity

    Synonyms: Heme-controlled repressor, Heme-regulated inhibitor
  5. Drug

    Phenindione

    go.drugbank.com/drugs/DB00498
    ApprovedInvestigational

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p234)

  6. Drug

    Insulin human

    go.drugbank.com/drugs/DB00030
    ApprovedInvestigational

    Afrezza does not currently have Health Canada or European Medicines Agency approval for marketing in Canada or the EU. … Unfortunately, limited uptake by physicians and patients, poor sales, bulky packaging, and concerns over the possible impact on lung cancer development resulted in Exubera products being withdrawn from

    Mixtures: INSUMAN COMB 25 100I E/ML, INSUMAN COMB 25 100I E/MLProducts: Humulin U, Humulin R U-500
  7. Drug

    Ganaxolone

    go.drugbank.com/drugs/DB05087
    ApprovedInvestigational

    [L41130] It was approved under the brand name ZTALMY by the US FDA in March 2022 for the treatment of seizures associated with CDKL5 deficiency disorder (CDD), becoming the first FDA-approved treatment

  8. Drug

    Aluminum sulfate

    go.drugbank.com/drugs/DB11239
    Approved

    Aluminum (Al), also spelled aluminum, chemical element, a lightweight, silvery-white metal of main Group 13 (IIIa, or boron group) of the periodic table . It is a chemical agent used in water purification, the pH regulation of garden soi...

  9. Drug

    Prazosin

    go.drugbank.com/drugs/DB00457
    ApprovedInvestigational

    Prazosin is marketed by _Pfizer_ and was initially approved by the FDA in 1988.[L5828] It belongs to the class of drugs known as alpha-1 antagonists.

    Products: Nu-prazo Tab 1mg, Nu-prazo Tab 2mg
  10. Drug

    Bulevirtide

    go.drugbank.com/drugs/DB15248
    ApprovedInvestigational

    It was first approved for use in the EU on May 28, 2020; bulevirtide has been granted PRIME scheme eligibility and Orphan Drug Designation by the European Medicines Agency.